Brokerages Expect Heron Therapeutics Inc (HRTX) Will Post Earnings of -$0.48 Per Share
Analysts forecast that Heron Therapeutics Inc (NASDAQ:HRTX) will announce earnings per share (EPS) of ($0.48) for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Heron Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.29) and the lowest estimate coming in at ($0.60). Heron Therapeutics posted earnings of ($0.77) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 37.7%. The business is expected to report its next quarterly earnings results on Monday, November 5th.
On average, analysts expect that Heron Therapeutics will report full-year earnings of ($2.22) per share for the current year, with EPS estimates ranging from ($2.56) to ($1.86). For the next financial year, analysts expect that the business will report earnings of ($0.59) per share, with EPS estimates ranging from ($1.48) to $0.45. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Heron Therapeutics.
Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.54) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.14. The firm had revenue of $17.28 million for the quarter, compared to analyst estimates of $12.82 million. Heron Therapeutics had a negative net margin of 411.41% and a negative return on equity of 112.35%. The business’s revenue for the quarter was up 103.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.80) EPS.
Shares of HRTX stock traded up $0.10 during trading on Monday, hitting $38.20. 704,400 shares of the stock traded hands, compared to its average volume of 1,213,213. The firm has a market cap of $3.01 billion, a PE ratio of 10.47 and a beta of 1.56. Heron Therapeutics has a 52-week low of $14.40 and a 52-week high of $42.90.
In related news, President Robert Rosen sold 129,469 shares of Heron Therapeutics stock in a transaction that occurred on Friday, June 29th. The shares were sold at an average price of $39.59, for a total value of $5,125,677.71. Following the completion of the sale, the president now owns 132,109 shares in the company, valued at approximately $5,230,195.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Barry D. Quart sold 50,000 shares of Heron Therapeutics stock in a transaction that occurred on Thursday, June 21st. The shares were sold at an average price of $39.05, for a total transaction of $1,952,500.00. Following the completion of the sale, the chief executive officer now owns 69,600 shares of the company’s stock, valued at approximately $2,717,880. The disclosure for this sale can be found here. Insiders sold a total of 440,469 shares of company stock valued at $17,218,958 in the last quarter. 16.20% of the stock is owned by insiders.
A number of institutional investors have recently bought and sold shares of HRTX. Eagle Asset Management Inc. acquired a new stake in Heron Therapeutics in the 1st quarter valued at approximately $50,005,000. Carillon Tower Advisers Inc. acquired a new stake in Heron Therapeutics in the 1st quarter valued at approximately $33,651,000. BlackRock Inc. increased its holdings in Heron Therapeutics by 29.4% in the 2nd quarter. BlackRock Inc. now owns 4,544,731 shares of the biotechnology company’s stock valued at $176,563,000 after purchasing an additional 1,032,010 shares during the last quarter. FMR LLC grew its stake in shares of Heron Therapeutics by 6.5% in the second quarter. FMR LLC now owns 11,290,956 shares of the biotechnology company’s stock worth $438,654,000 after acquiring an additional 693,699 shares in the last quarter. Finally, Nexthera Capital LP acquired a new position in shares of Heron Therapeutics in the first quarter worth $11,288,000.
About Heron Therapeutics
Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Featured Article: What does RSI mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.